\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ heart\\ size\\.\\ linear\\ interstitial\\ pattern\\ in\\ bilateral\\ bases\\ with\\ bilateral\\ blunting\\ of\\ the\\ costophrenic\\ angles\\.\\ flattening\\ of\\ the\\ hemidiaphragms\\.\\ pleural\\ thickening\\.\\ minor\\ fissure\\ visualized\\ on\\ pa\\.\\ bones\\ and\\ soft\\ tissues\\ are\\ unremarkable\\.\ \(0\)\
\-\ chronic\\ interstitial\\ lung\\ disease\\ secondary\\ to\\ sle\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 55yo\\ african\\ american\\ female\\ with\\ a\\ 30\\ year\\ history\\ of\\ sle\\ manifested\\ by\\ proteinuria\\,\\ jaccoud\\'s\\ arthritis\\,\\ h\\/o\\ cns\\ vasculitis\\,\\ discoid\\ lesions\\,\\ and\\ chronic\\ interstitial\\ lung\\ disease\\ who\\ presented\\ with\\ a\\ non\\-productive\\ cough\\,\\ clear\\ rhinorrhea\\,\\ and\\ an\\ increase\\ in\\ her\\ home\\ oxygen\\ requirement\\ from\\ 2lnc\\ to\\ 3lnc\\.\\ pt\\ complained\\ of\\ shortness\\ of\\ breath\\ without\\ chest\\ pain\\ that\\ progressed\\ over\\ three\\ days\\ prior\\ to\\ admission\\.\\ pt\\ reported\\ that\\ she\\ increased\\ her\\ use\\ of\\ her\\ albuterol\\ inhaler\\ with\\ minimal\\ relief\\ of\\ her\\ dyspnea\\.\\ pt\\ denied\\ any\\ fevers\\,\\ chills\\,\\ night\\ sweats\\,\\ nausea\\,\\ vomiting\\,\\ or\\ diarrhea\\.\\ pt\\ was\\ afebrile\\ and\\ her\\ wbc\\ was\\ wnl\\.\\ pt\\ was\\ on\\ prednisone\\ chronically\\.\ \(0\)\
\-\ systemic\\ lupus\\ erythematosus\\ is\\ an\\ autoimmune\\ disease\\ with\\ a\\ peak\\ incidence\\ in\\ females\\ between\\ the\\ ages\\ of\\ 15\\ and\\ 40\\.\\ the\\ female\\ to\\ male\\ ratio\\ is\\ about\\ 5\\:1\\.\\ in\\ the\\ united\\ states\\,\\ sle\\ is\\ more\\ prevalent\\ among\\ blacks\\ and\\ hispanics\\.\\ sle\\ occurs\\ with\\ a\\ much\\ higher\\ frequency\\ among\\ first\\ degree\\ relatives\\.\\ also\\,\\ within\\ extended\\ families\\ other\\ autoimmune\\ conditions\\ such\\ as\\ hemolytic\\ anemia\\,\\ idiopathic\\ thrombocytopenia\\ purpura\\,\\ and\\ thyroiditis\\ may\\ be\\ found\\ in\\ addition\\ to\\ sle\\.\\ although\\ sle\\ demonstrates\\ a\\ hereditary\\ influence\\,\\ most\\ cases\\ of\\ sle\\ are\\ sporadic\\ and\\ idiopathic\\.\ \(0\)\
\-\ pulmonary\\ disease\\ is\\ a\\ relatively\\ common\\ manifestation\\ of\\ sle\\.\\ however\\,\\ the\\ specific\\ clinical\\ manifestations\\ of\\ sle\\ involvement\\ of\\ the\\ respiratory\\ system\\ are\\ very\\ diverse\\.\\ these\\ manifestations\\ include\\ acute\\ lupus\\ pneumonitis\\,\\ chronic\\ interstitial\\ lung\\ disease\\,\\ pulmonary\\ hemorrhage\\,\\ pulmonary\\ embolism\\,\\ pulmonary\\ hypertension\\,\\ and\\ shrinking\\ lung\\ syndrome\\.\\ lupus\\ pneumonitis\\ can\\ present\\ as\\ an\\ acute\\ illness\\ or\\ as\\ a\\ chronic\\ process\\.\ \(0\)\
\-\ acute\\ lupus\\ pneumonitis\\ is\\ uncommon\\.\\ it\\ presents\\ with\\ the\\ same\\ signs\\ and\\ symptoms\\ as\\ an\\ infectious\\ pneumonia\\;\\ cough\\,\\ fever\\,\\ dyspnea\\,\\ patchy\\ alveolar\\ infiltrates\\ on\\ chest\\ \\.radiography\\,\\ and\\ occasionally\\ hemoptysis\\ with\\ a\\ drop\\ in\\ hematocrit\\.\\ often\\ the\\ acute\\ lupus\\ pulmonary\\ disease\\ is\\ accompanied\\ by\\ other\\ signs\\ of\\ sle\\ exacerbation\\.\\ when\\ there\\ is\\ a\\ doubt\\ as\\ to\\ the\\ etiology\\ of\\ the\\ pulmonary\\ infiltrates\\,\\ a\\ bronchoalveolar\\ lavage\\ is\\ indicated\\.\\ the\\ accepted\\ first\\ line\\ treatment\\ is\\ glucocorticoids\\.\\ when\\ hemoptysis\\ is\\ present\\,\\ it\\ is\\ thought\\ to\\ be\\ the\\ result\\ of\\ pulmonary\\ hemorrhage\\ due\\ to\\ pulmonary\\ vasculitis\\.\\ for\\ the\\ pulmonary\\ hemorrhage\\ syndromes\\ of\\ acute\\ immune\\-mediated\\ lung\\ injury\\ in\\ sle\\ patients\\,\\ pulse\\ methylprednisone\\ therapy\\ may\\ be\\ effective\\.\\ for\\ critically\\ ill\\ patients\\,\\ the\\ addition\\ of\\ azathioprine\\ or\\ cyclophosphamide\\ to\\ the\\ glucocorticoids\\ is\\ recommended\\.\\ the\\ reported\\ overall\\ mortality\\ rate\\ for\\ acute\\ lupus\\ pneumonitis\\ is\\ over\\ 50\\%\\ despite\\ treatment\\.\ \(0\)\
\-\ the\\ chronic\\ form\\ of\\ lupus\\ pneumonitis\\ can\\ result\\ as\\ a\\ consequence\\ of\\ previous\\ insult\\ to\\ the\\ lungs\\ from\\ acute\\ pneumonitis\\ or\\ can\\ be\\ an\\ independent\\ manifestation\\ of\\ sle\\.\\ it\\ is\\ characterized\\ by\\ exertional\\ dyspnea\\,\\ non\\-productive\\ cough\\,\\ basilar\\ rales\\,\\ and\\ radiographic\\ findings\\ consistent\\ with\\ interstitial\\ lung\\ disease\\.\\ often\\ radiographic\\ findings\\ of\\ interstitial\\ lung\\ disease\\ may\\ be\\ noted\\ prior\\ to\\ clinical\\ symptoms\\ being\\ manifested\\.\\ the\\ major\\ clinical\\ question\\ that\\ must\\ be\\ addressed\\ in\\ chronic\\ lupus\\ pneumonitis\\ is\\ whether\\ inflammatory\\ alveolitis\\ present\\.\\ inflammatory\\ alveolitis\\ can\\ be\\ treated\\ with\\ immunosuppression\\ where\\ as\\ chronic\\ fibrosis\\ is\\ not\\ treatable\\.\\ discriminating\\ between\\ inflammatory\\ alveolitis\\ and\\ chronic\\ fibrosis\\ can\\ be\\ difficult\\.\\ a\\ reticular\\ pattern\\ with\\ honeycombing\\ on\\ high\\ resolution\\ ct\\ is\\ suggestive\\ of\\ irreversible\\ fibrosis\\.\\ a\\ ground\\-glass\\ appearance\\ is\\ indicative\\ of\\ active\\ inflammation\\ on\\ high\\ resolution\\ ct\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sle\\:\\ 0\\.42163703745544545\ \(0\)\
\-\ lupus\\:\\ 0\\.27598433525184646\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.2679861666999297\ \(0\)\
\-\ pulmonary\\:\\ 0\\.1816092220451032\ \(0\)\
\-\ interstitial\\:\\ 0\\.1800655256629665\ \(0\)\
\-\ is\\:\\ 0\\.17225266563094604\ \(0\)\
\-\ chronic\\:\\ 0\\.15719973113935362\ \(0\)\
\-\ of\\:\\ 0\\.14900391169216184\ \(0\)\
\-\ lung\\:\\ 0\\.14096553345404783\ \(0\)\
\-\ the\\:\\ 0\\.13871706717983273\ \(0\)\
\-\ alveolitis\\:\\ 0\\.13701375569738003\ \(0\)\
\-\ acute\\:\\ 0\\.12535840089459171\ \(0\)\
\-\ pt\\:\\ 0\\.11912149833824957\ \(0\)\
\-\ disease\\:\\ 0\\.11116920466771195\ \(0\)\
\-\ be\\:\\ 0\\.10743382240787618\ \(0\)\
\-\ her\\:\\ 0\\.10340949645968343\ \(0\)\
\-\ as\\:\\ 0\\.09309515320168157\ \(0\)\
\-\ to\\:\\ 0\\.091037036593165\ \(0\)\
\-\ and\\:\\ 0\\.08892868332890673\ \(0\)\
\-\ dyspnea\\:\\ 0\\.08739687013156605\ \(0\)\
\-\ manifested\\:\\ 0\\.08720265757895748\ \(0\)\
\-\ can\\:\\ 0\\.08686132381084673\ \(0\)\
\-\ fibrosis\\:\\ 0\\.08319819913104921\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.08174743068216002\ \(0\)\
\-\ manifestation\\:\\ 0\\.07525209552247833\ \(0\)\
\-\ cough\\:\\ 0\\.07414708203744491\ \(0\)\
\-\ autoimmune\\:\\ 0\\.07407072657747853\ \(0\)\
\-\ infiltrates\\:\\ 0\\.07299857013193387\ \(0\)\
\-\ with\\:\\ 0\\.07130531984490499\ \(0\)\
\-\ among\\:\\ 0\\.07000600538493536\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.0685222720620924\ \(0\)\
\-\ manifestations\\:\\ 0\\.06784595789116768\ \(0\)\
\-\ inflammatory\\:\\ 0\\.06715521875626618\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.06649315555613784\ \(0\)\
\-\ in\\:\\ 0\\.06588287453643463\ \(0\)\
\-\ an\\:\\ 0\\.06329551042788639\ \(0\)\
\-\ clinical\\:\\ 0\\.06294048819906319\ \(0\)\
\-\ vasculitis\\:\\ 0\\.06144485959107462\ \(0\)\
\-\ idiopathic\\:\\ 0\\.056005413493598236\ \(0\)\
\-\ resolution\\:\\ 0\\.053719421575275796\ \(0\)\
\-\ addition\\:\\ 0\\.0535904560694296\ \(0\)\
\-\ 55yo\\:\\ 0\\.05294152154791128\ \(0\)\
\-\ jaccoud\\:\\ 0\\.05294152154791128\ \(0\)\
\-\ 2lnc\\:\\ 0\\.05294152154791128\ \(0\)\
\-\ 3lnc\\:\\ 0\\.05294152154791128\ \(0\)\
\-\ hispanics\\:\\ 0\\.05294152154791128\ \(0\)\
\-\ present\\:\\ 0\\.05096119343944881\ \(0\)\
\-\ it\\:\\ 0\\.05083740302541068\ \(0\)\
\-\ diverse\\:\\ 0\\.05058845018225584\ \(0\)\
\-\ methylprednisone\\:\\ 0\\.05058845018225584\ \(0\)\
\-\ discriminating\\:\\ 0\\.05058845018225584\ \(0\)\
\-\ on\\:\\ 0\\.049990843109708055\ \(0\)\
\-\ may\\:\\ 0\\.049977891668978786\ \(0\)\
\-\ result\\:\\ 0\\.04956661413060995\ \(0\)\
\-\ pattern\\:\\ 0\\.049431388024963274\ \(0\)\
\-\ radiographic\\:\\ 0\\.04912185565176327\ \(0\)\
\-\ discoid\\:\\ 0\\.048918919478967524\ \(0\)\
\-\ inhaler\\:\\ 0\\.048918919478967524\ \(0\)\
\-\ reported\\:\\ 0\\.047687096140450844\ \(0\)\
\-\ families\\:\\ 0\\.0476239308584225\ \(0\)\
\-\ shrinking\\:\\ 0\\.0476239308584225\ \(0\)\
\-\ critically\\:\\ 0\\.0476239308584225\ \(0\)\
\-\ relatives\\:\\ 0\\.04656584811331209\ \(0\)\
\-\ independent\\:\\ 0\\.04656584811331209\ \(0\)\
\-\ signs\\:\\ 0\\.046272980477181265\ \(0\)\
\-\ or\\:\\ 0\\.04606605502756997\ \(0\)\
\-\ blacks\\:\\ 0\\.04567125189912668\ \(0\)\
\-\ influence\\:\\ 0\\.04567125189912668\ \(0\)\
\-\ treatable\\:\\ 0\\.04567125189912668\ \(0\)\
\-\ doubt\\:\\ 0\\.04489631741002376\ \(0\)\
\-\ azathioprine\\:\\ 0\\.04489631741002376\ \(0\)\
\-\ immunosuppression\\:\\ 0\\.04489631741002376\ \(0\)\
\-\ first\\:\\ 0\\.044680517777367056\ \(0\)\
\-\ irreversible\\:\\ 0\\.04421277674765665\ \(0\)\
\-\ hemidiaphragms\\:\\ 0\\.04360132878947874\ \(0\)\
\-\ accepted\\:\\ 0\\.04360132878947874\ \(0\)\
\-\ often\\:\\ 0\\.04320154718586407\ \(0\)\
\-\ that\\:\\ 0\\.04309851301647606\ \(0\)\
\-\ requirement\\:\\ 0\\.04304820683035519\ \(0\)\
\-\ chronically\\:\\ 0\\.04304820683035519\ \(0\)\
\-\ thrombocytopenia\\:\\ 0\\.04304820683035519\ \(0\)\
\-\ addressed\\:\\ 0\\.04304820683035519\ \(0\)\
\-\ between\\:\\ 0\\.0430195783236956\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.04254324604436833\ \(0\)\
\-\ prevalent\\:\\ 0\\.04254324604436833\ \(0\)\
\-\ consequence\\:\\ 0\\.04254324604436833\ \(0\)\
\-\ exertional\\:\\ 0\\.04254324604436833\ \(0\)\
\-\ by\\:\\ 0\\.04217444662608418\ \(0\)\
\-\ proteinuria\\:\\ 0\\.04207872715065902\ \(0\)\
\-\ purpura\\:\\ 0\\.04207872715065902\ \(0\)\
\-\ insult\\:\\ 0\\.04164864983018292\ \(0\)\
\-\ honeycombing\\:\\ 0\\.04164864983018292\ \(0\)\
\-\ albuterol\\:\\ 0\\.0412482574238233\ \(0\)\
\-\ hemolytic\\:\\ 0\\.0412482574238233\ \(0\)\
\-\ lavage\\:\\ 0\\.0412482574238233\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.0412482574238233\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.04087371534108001\ \(0\)\
\-\ when\\:\\ 0\\.039994232666148245\ \(0\)\
\-\ angles\\:\\ 0\\.03987640161255376\ \(0\)\
\-\ erythematosus\\:\\ 0\\.039295578464527484\ \(0\)\
\-\ blunting\\:\\ 0\\.038767633933424826\ \(0\)\
\-\ costophrenic\\:\\ 0\\.03805612508171526\ \(0\)\
\-\ reticular\\:\\ 0\\.03783710331305745\ \(0\)\
\-\ are\\:\\ 0\\.03768511251479831\ \(0\)\
\-\ high\\:\\ 0\\.03762901329950077\ \(0\)\
\-\ sporadic\\:\\ 0\\.037626047761239165\ \(0\)\
\-\ patients\\:\\ 0\\.037246337667779884\ \(0\)\
\-\ prior\\:\\ 0\\.03704420517891638\ \(0\)\
\-\ over\\:\\ 0\\.03681526726141156\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.036672533395756\ \(0\)\
\-\ exacerbation\\:\\ 0\\.036331059140694136\ \(0\)\
\-\ symptoms\\:\\ 0\\.03622596424808261\ \(0\)\
\-\ united\\:\\ 0\\.03616757260976913\ \(0\)\
\-\ accompanied\\:\\ 0\\.03616757260976913\ \(0\)\
\-\ drop\\:\\ 0\\.03600856573021\ \(0\)\
\-\ bilateral\\:\\ 0\\.035583307091480915\ \(0\)\
\-\ chest\\:\\ 0\\.0349486099663219\ \(0\)\
\-\ prednisone\\:\\ 0\\.034872583989224104\ \(0\)\
\-\ alveolar\\:\\ 0\\.034745031864481066\ \(0\)\
\-\ was\\:\\ 0\\.034611881292533536\ \(0\)\
\-\ other\\:\\ 0\\.03438353902593707\ \(0\)\
\-\ progressed\\:\\ 0\\.03437838018139832\ \(0\)\
\-\ hematocrit\\:\\ 0\\.0342611360310462\ \(0\)\
\-\ extended\\:\\ 0\\.0341462137003115\ \(0\)\
\-\ question\\:\\ 0\\.0341462137003115\ \(0\)\
\-\ bases\\:\\ 0\\.03403352301277151\ \(0\)\
\-\ oxygen\\:\\ 0\\.03403352301277151\ \(0\)\
\-\ hereditary\\:\\ 0\\.03403352301277151\ \(0\)\
\-\ syndromes\\:\\ 0\\.03403352301277151\ \(0\)\
\-\ indicative\\:\\ 0\\.03403352301277151\ \(0\)\
\-\ peak\\:\\ 0\\.03392297894558384\ \(0\)\
\-\ sweats\\:\\ 0\\.0338145012441137\ \(0\)\
\-\ ages\\:\\ 0\\.0338145012441137\ \(0\)\
\-\ effective\\:\\ 0\\.0338145012441137\ \(0\)\
\-\ females\\:\\ 0\\.03330059151563448\ \(0\)\
\-\ illness\\:\\ 0\\.03330059151563448\ \(0\)\
\-\ ratio\\:\\ 0\\.033203053285935785\ \(0\)\
\-\ findings\\:\\ 0\\.03267693243948908\ \(0\)\
\-\ flattening\\:\\ 0\\.03264993132681224\ \(0\)\
\-\ mortality\\:\\ 0\\.03256266068892223\ \(0\)\
\-\ rales\\:\\ 0\\.03256266068892223\ \(0\)\
\-\ whether\\:\\ 0\\.03239196049882563\ \(0\)\
\-\ fissure\\:\\ 0\\.032308457071750375\ \(0\)\
\-\ patchy\\:\\ 0\\.032226138130454586\ \(0\)\
\-\ female\\:\\ 0\\.031949028528260724\ \(0\)\
\-\ complained\\:\\ 0\\.031908064665390756\ \(0\)\
\-\ occasionally\\:\\ 0\\.031755335112626834\ \(0\)\
\-\ treatment\\:\\ 0\\.03153899043295809\ \(0\)\
\-\ frequency\\:\\ 0\\.03146142987845826\ \(0\)\
\-\ diarrhea\\:\\ 0\\.03131987681072086\ \(0\)\
\-\ basilar\\:\\ 0\\.03131987681072086\ \(0\)\
\-\ pulse\\:\\ 0\\.03125037432663996\ \(0\)\
\-\ ill\\:\\ 0\\.03125037432663996\ \(0\)\
\-\ minor\\:\\ 0\\.031113817719010027\ \(0\)\
\-\ relief\\:\\ 0\\.031046725780366217\ \(0\)\
\-\ wnl\\:\\ 0\\.031046725780366217\ \(0\)\
\-\ cns\\:\\ 0\\.030914824919521345\ \(0\)\
\-\ anemia\\:\\ 0\\.030415300563024623\ \(0\)\
\-\ overall\\:\\ 0\\.030415300563024623\ \(0\)\
\-\ characterized\\:\\ 0\\.030415300563024623\ \(0\)\
\-\ conditions\\:\\ 0\\.030238533962102437\ \(0\)\
\-\ chills\\:\\ 0\\.030123611631367737\ \(0\)\
\-\ for\\:\\ 0\\.03010128426964321\ \(0\)\
\-\ higher\\:\\ 0\\.030066992762214296\ \(0\)\
\-\ embolism\\:\\ 0\\.03001092094382775\ \(0\)\
\-\ uncommon\\:\\ 0\\.029955385706094937\ \(0\)\
\-\ african\\:\\ 0\\.029900376876640083\ \(0\)\
\-\ denied\\:\\ 0\\.029900376876640083\ \(0\)\
\-\ night\\:\\ 0\\.02973841134901466\ \(0\)\
\-\ systemic\\:\\ 0\\.02937719507707789\ \(0\)\
\-\ home\\:\\ 0\\.02927798944669072\ \(0\)\
\-\ fevers\\:\\ 0\\.02922901541718233\ \(0\)\
\-\ states\\:\\ 0\\.02908452526346882\ \(0\)\
\-\ degree\\:\\ 0\\.028943545341557412\ \(0\)\
\-\ form\\:\\ 0\\.028943545341557412\ \(0\)\
\-\ major\\:\\ 0\\.028943545341557412\ \(0\)\
\-\ despite\\:\\ 0\\.028805909134248735\ \(0\)\
\-\ much\\:\\ 0\\.028671461699113873\ \(0\)\
\-\ afebrile\\:\\ 0\\.028583529894825394\ \(0\)\
\-\ thought\\:\\ 0\\.028583529894825394\ \(0\)\
\-\ incidence\\:\\ 0\\.02849691055462491\ \(0\)\
\-\ must\\:\\ 0\\.02836935842988187\ \(0\)\
\-\ american\\:\\ 0\\.028244549575365447\ \(0\)\
\-\ admission\\:\\ 0\\.027620767100203513\ \(0\)\
\-\ difficult\\:\\ 0\\.02747476221569646\ \(0\)\
\-\ indicated\\:\\ 0\\.027227772257696205\ \(0\)\
\-\ relatively\\:\\ 0\\.026957798554580158\ \(0\)\
\-\ suggestive\\:\\ 0\\.026957798554580158\ \(0\)\
\-\ arthritis\\:\\ 0\\.02692491808103528\ \(0\)\
\-\ linear\\:\\ 0\\.026668372971777456\ \(0\)\
\-\ etiology\\:\\ 0\\.026668372971777456\ \(0\)\
\-\ bones\\:\\ 0\\.026637087785196308\ \(0\)\
\-\ infectious\\:\\ 0\\.026637087785196308\ \(0\)\
\-\ inflammation\\:\\ 0\\.026605970348410845\ \(0\)\
\-\ increase\\:\\ 0\\.026575018872077125\ \(0\)\
\-\ shortness\\:\\ 0\\.02654423159532909\ \(0\)\
\-\ respiratory\\:\\ 0\\.0263331760435108\ \(0\)\
\-\ recommended\\:\\ 0\\.0263331760435108\ \(0\)\
\-\ from\\:\\ 0\\.0262955166930922\ \(0\)\
\-\ same\\:\\ 0\\.026186987254323037\ \(0\)\
\-\ pneumonia\\:\\ 0\\.02612952749723705\ \(0\)\
\-\ tissues\\:\\ 0\\.026101009562423977\ \(0\)\
\-\ occurs\\:\\ 0\\.026101009562423977\ \(0\)\
\-\ where\\:\\ 0\\.026016287064226436\ \(0\)\
\-\ visualized\\:\\ 0\\.02585046469585539\ \(0\)\
\-\ line\\:\\ 0\\.02579622702952124\ \(0\)\
\-\ nausea\\:\\ 0\\.025430126239984526\ \(0\)\
\-\ pa\\:\\ 0\\.025404839106048526\ \(0\)\
\-\ use\\:\\ 0\\.025329632160809894\ \(0\)\
\-\ hypertension\\:\\ 0\\.025329632160809894\ \(0\)\
\-\ minimal\\:\\ 0\\.02525538737774696\ \(0\)\
\-\ system\\:\\ 0\\.02525538737774696\ \(0\)\
\-\ ct\\:\\ 0\\.025206492277871483\ \(0\)\
\-\ specific\\:\\ 0\\.025085756443859065\ \(0\)\
\-\ rate\\:\\ 0\\.025085756443859065\ \(0\)\
\-\ previous\\:\\ 0\\.0250145483350616\ \(0\)\
\-\ pleural\\:\\ 0\\.02492094327261365\ \(0\)\
\-\ process\\:\\ 0\\.024828824067706003\ \(0\)\
\-\ about\\:\\ 0\\.024783307065304974\ \(0\)\
\-\ active\\:\\ 0\\.024582786187151297\ \(0\)\
\-\ vomiting\\:\\ 0\\.02449584241783309\ \(0\)\
\-\ lungs\\:\\ 0\\.024431478859135658\ \(0\)\
\-\ breath\\:\\ 0\\.024263252933862858\ \(0\)\
\-\ clear\\:\\ 0\\.02399987773976506\ \(0\)\
\-\ involvement\\:\\ 0\\.023960398757201934\ \(0\)\
\-\ very\\:\\ 0\\.02374793819676854\ \(0\)\
\-\ wbc\\:\\ 0\\.023398341633793937\ \(0\)\
\-\ 50\\:\\ 0\\.02311944650223941\ \(0\)\
\-\ being\\:\\ 0\\.02306861358112251\ \(0\)\
\-\ heart\\:\\ 0\\.023018222051287996\ \(0\)\
\-\ 30\\:\\ 0\\.022583368279467088\ \(0\)\
\-\ although\\:\\ 0\\.022537002748769394\ \(0\)\
\-\ thickening\\:\\ 0\\.022521629526385332\ \(0\)\
\-\ fever\\:\\ 0\\.022445368401982326\ \(0\)\
\-\ size\\:\\ 0\\.022415142354194287\ \(0\)\
\-\ 15\\:\\ 0\\.022370096425137105\ \(0\)\
\-\ cases\\:\\ 0\\.02226632937863745\ \(0\)\
\-\ three\\:\\ 0\\.022222419549565556\ \(0\)\
\-\ unremarkable\\:\\ 0\\.02219332982421492\ \(0\)\
\-\ injury\\:\\ 0\\.021587688157723287\ \(0\)\
\-\ found\\:\\ 0\\.021420209177307217\ \(0\)\
\-\ any\\:\\ 0\\.021394866831113104\ \(0\)\
\-\ such\\:\\ 0\\.021294589812597953\ \(0\)\
\-\ days\\:\\ 0\\.020956667202724256\ \(0\)\
\-\ treated\\:\\ 0\\.020615192947662397\ \(0\)\
\-\ syndrome\\:\\ 0\\.019957502608911604\ \(0\)\
\-\ appearance\\:\\ 0\\.019957502608911604\ \(0\)\
\-\ she\\:\\ 0\\.019706401729115638\ \(0\)\
\-\ include\\:\\ 0\\.019696957645572815\ \(0\)\
\-\ secondary\\:\\ 0\\.019621953201792983\ \(0\)\
\-\ however\\:\\ 0\\.01959407458265738\ \(0\)\
\-\ presented\\:\\ 0\\.019304749223292523\ \(0\)\
\-\ due\\:\\ 0\\.019029165671449327\ \(0\)\
\-\ therapy\\:\\ 0\\.01902076105295454\ \(0\)\
\-\ lesions\\:\\ 0\\.019012368588648364\ \(0\)\
\-\ common\\:\\ 0\\.018774121044485934\ \(0\)\
\-\ who\\:\\ 0\\.0187260263930686\ \(0\)\
\-\ these\\:\\ 0\\.018694183306009436\ \(0\)\
\-\ more\\:\\ 0\\.01817798652802029\ \(0\)\
\-\ consistent\\:\\ 0\\.01795009415823017\ \(0\)\
\-\ increased\\:\\ 0\\.01790141356554367\ \(0\)\
\-\ soft\\:\\ 0\\.017624204305165866\ \(0\)\
\-\ noted\\:\\ 0\\.01755203009214504\ \(0\)\
\-\ without\\:\\ 0\\.017461451405245736\ \(0\)\
\-\ most\\:\\ 0\\.017228655578181446\ \(0\)\
\-\ demonstrates\\:\\ 0\\.016631409672661936\ \(0\)\
\-\ presents\\:\\ 0\\.01592503921549422\ \(0\)\
\-\ also\\:\\ 0\\.015571472513713621\ \(0\)\
\-\ within\\:\\ 0\\.015246974997863346\ \(0\)\
\-\ male\\:\\ 0\\.0147394578945338\ \(0\)\
\-\ normal\\:\\ 0\\.013516401332981189\ \(0\)\
\-\ there\\:\\ 0\\.013172232344046545\ \(0\)\
\-\ not\\:\\ 0\\.013068923231714158\ \(0\)\
\-\ history\\:\\ 0\\.012647887805650364\ \(0\)\
\-\ pain\\:\\ 0\\.011846057431617363\ \(0\)\
\-\ patient\\:\\ 0\\.010767276542892619\ \(0\)\
\-\ year\\:\\ 0\\.010202197365063649\ \(0\)\
